A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck

Seiwert, TY
Fayette, J
Cupissol, D
Del Campo, JM
Clement, Paul
Hitt, R
Degardin, M
Zhang, W
Blackman, A
Ehrnrooth, E
Cohen, EEW

September 2014

Afatinib is an oral, irreversible ErbB family blocker that has shown activity in epidermal growth fa...

Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer

Martin, Nicolas
Isambert, Nicolas
Gomez-Roca, Carlos
Goeldner, Rainer-Georg
Zanetta, Sylvie
Sadrolhefazi, Behbood
de Mont-Serrat, Helene
Campone, Mario
Delord, Jean-Pierre

December 2018

IF 2.808International audienceBackgroundTrastuzumab is the mainstay of therapy for patients with HER...

Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)

Dziadziuszko, Rafal
Smit, Egbert F
Dafni, Urania
Wolf, Juergen
Wasąg, Bartosz
Biernat, Wojciech
Finn, Stephen P
Kammler, Roswitha
Tsourti, Zoi
Rabaglio, Manuela
Ruepp, Barbara
Roschitzki-Voser, Heidi
Stahel, Rolf A
Felip, Enriqueta
Peters, Solange

June 2019

INTRODUCTION Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed in approxi...

CLINICAL TRIAL

Nancy U. Lin
Eric P. Winer
Duncan Wheatley
Lisa A. Carey
Stephen Houston
David Mendelson
Pamela Munster
Laurie Frakes
Steve Kelly
Agustin A. Garcia
Susan Cleator
Martina Uttenreuther-fischer
Hilary Jones
Sven Wind
Richard Vinisko
Tamas Hickish
N. U. Lin
E. P. Winer
E. P. Winer
D. Wheatley

August 2016

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2...

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

Lin, Nancy U.
Winer, Eric P.
Wheatley, Duncan
Carey, Lisa A.
Houston, Stephen
Mendelson, David
Munster, Pamela
Frakes, Laurie
Kelly, Steve
Garcia, Agustin A.
Cleator, Susan
Uttenreuther-Fischer, Martina
Jones, Hilary
Wind, Sven
Vinisko, Richard
Hickish, Tamas

January 2012

Afatinib is an oral, ErbB family blocker, which covalently binds and irreversibly blocks all kinase-...

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.

Schuler, M
Awada, Ahmad
Harter, Philipp
Canon, Jean-Luc
Possinger, Kurt
Schmidt, M
De Greve, Jacques
Neven, Patrick
Dirix, Luc Y
Jonat, Walter
Beckmann, Matthias W
Schütte, Jochen
Fasching, Peter A
Gottschalk, Nina
Besse-Hammer, Tatiana
Fleischer, Frank
Wind, Sven
Uttenreuther-Fischer, Martina
Piccart-Gebhart, Martine
Harbeck, Nadia

August 2012

Afatinib (BIBW 2992) is an ErbB-family blocker that irreversibly inhibits signaling from all relevan...

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer

Schuler, Martin
Awada, Ahmad
Harter, Philipp
Canon, Jean Luc
Possinger, Kurt
Schmidt, Marcus
De Grève, Jacques
Neven, Patrick
Dirix, Luc
Jonat, Walter
Beckmann, Matthias W
Schütte, Jochen
Fasching, Peter A
Gottschalk, Nina
Besse-Hammer, Tatiana
Fleischer, Frank
Wind, Sven
Uttenreuther-Fischer, Martina
Piccart, Martine
Harbeck, Nadia

August 2012

Afatinib (BIBW 2992) is an ErbB-family blocker that irreversibly inhibits signaling from all relevan...

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma

De Grève, Jacques
Moran, Teresa
Graas, Marie-Pascale
Galdermans, Daniella
Vuylsteke, Peter
Canon, Jean-Luc
Schallier, Denis
Decoster, Lore
Teugels, Erik
Massey, Dan
Chand, Vikram K
Vansteenkiste, Johan

April 2015

Afatinib, an oral irreversible ErbB family blocker, has demonstrated efficacy in patients with epide...

in

David A. Reardon
Louis B. Nabors
Warren P. Mason
James R. Perry
William Shapiro
Petr Kavan
David Mathieu
Surasak Phuphanich
Agnieszka Cseh
Yali Fu
Julie Cong
Sven Wind

October 2016

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without ...

Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members

Khelwatty, Said Abdullah
Essapen, Sharadah
Seddon, Alan M.
Modjtahedi, Helmout

August 2011

Despite the approval of the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs...

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

De Greve, J.
Teugels, E.
Geers, C.
Decoster, L.
Galdermans, D.
De Mey, J.
Everaert, H.
Umelo, Ijeoma
In't Veld, P.
Schallier, D.

January 2012

Human epidermal growth factor receptor (HER)2/neu kinase domain mutations are found in approximately...

DOI 10.1186/s40064-015-1601-7

Katy Pelling
Sven Wind
Guilhem Bousquet

August 2016

A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients wi...

LUX-breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatinib (L)

Hickish, T
Tseng, LM
Udovitsa, D
Pelling, K
Uttenreuther-Fischer, MM
Mehta, AO
Kovalenko, N
LUX-Breast 2 Study Group
Tsang, J
Huang, CS

January 2012

This journal suppl. is the 2012 ASCO Meeting Abstracts Part 1Open Access JournalGeneral Poster Sessi...

A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole

Gunzer, Katharina
Joly, Florence
Ferrero, Jean-Marc
Gligorov, Joseph
de Mont-Serrat, Helene
Uttenreuther-Fischer, Martina
Pelling, Katy
Wind, Sven
Bousquet, Guilhem
Misset, Jean-Louis

January 2016

International audiencePhase II, open‑label study assessing the efficacy and safety of the ErbB famil...

Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).

Dziadziuszko, Rafal
Smit, Egbert F
Dafni, Urania
Wolf, Juergen
Wasąg, Bartosz
Biernat, Wojciech
Finn, Stephen P
Kammler, Roswitha
Tsourti, Zoi
Rabaglio, Manuela
Ruepp, Barbara
Roschitzki-Voser, Heidi
Stahel, Rolf A
Felip, Enriqueta
Peters, Solange

June 2019

INTRODUCTION Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed in appro...

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck

Seiwert, TY
Fayette, J
Cupissol, D
Del Campo, JM
Clement, Paul
Hitt, R
Degardin, M
Zhang, W
Blackman, A
Ehrnrooth, E
Cohen, EEW

September 2014

Afatinib is an oral, irreversible ErbB family blocker that has shown activity in epidermal growth fa...

Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer

Martin, Nicolas
Isambert, Nicolas
Gomez-Roca, Carlos
Goeldner, Rainer-Georg
Zanetta, Sylvie
Sadrolhefazi, Behbood
de Mont-Serrat, Helene
Campone, Mario
Delord, Jean-Pierre

December 2018

IF 2.808International audienceBackgroundTrastuzumab is the mainstay of therapy for patients with HER...

Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)

Dziadziuszko, Rafal
Smit, Egbert F
Dafni, Urania
Wolf, Juergen
Wasąg, Bartosz
Biernat, Wojciech
Finn, Stephen P
Kammler, Roswitha
Tsourti, Zoi
Rabaglio, Manuela
Ruepp, Barbara
Roschitzki-Voser, Heidi
Stahel, Rolf A
Felip, Enriqueta
Peters, Solange

June 2019

INTRODUCTION Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed in approxi...

CLINICAL TRIAL

Nancy U. Lin
Eric P. Winer
Duncan Wheatley
Lisa A. Carey
Stephen Houston
David Mendelson
Pamela Munster
Laurie Frakes
Steve Kelly
Agustin A. Garcia
Susan Cleator
Martina Uttenreuther-fischer
Hilary Jones
Sven Wind
Richard Vinisko
Tamas Hickish
N. U. Lin
E. P. Winer
E. P. Winer
D. Wheatley

August 2016

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2...

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

Lin, Nancy U.
Winer, Eric P.
Wheatley, Duncan
Carey, Lisa A.
Houston, Stephen
Mendelson, David
Munster, Pamela
Frakes, Laurie
Kelly, Steve
Garcia, Agustin A.
Cleator, Susan
Uttenreuther-Fischer, Martina
Jones, Hilary
Wind, Sven
Vinisko, Richard
Hickish, Tamas

January 2012

Afatinib is an oral, ErbB family blocker, which covalently binds and irreversibly blocks all kinase-...

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.

Schuler, M
Awada, Ahmad
Harter, Philipp
Canon, Jean-Luc
Possinger, Kurt
Schmidt, M
De Greve, Jacques
Neven, Patrick
Dirix, Luc Y
Jonat, Walter
Beckmann, Matthias W
Schütte, Jochen
Fasching, Peter A
Gottschalk, Nina
Besse-Hammer, Tatiana
Fleischer, Frank
Wind, Sven
Uttenreuther-Fischer, Martina
Piccart-Gebhart, Martine
Harbeck, Nadia

August 2012

Afatinib (BIBW 2992) is an ErbB-family blocker that irreversibly inhibits signaling from all relevan...

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer

Schuler, Martin
Awada, Ahmad
Harter, Philipp
Canon, Jean Luc
Possinger, Kurt
Schmidt, Marcus
De Grève, Jacques
Neven, Patrick
Dirix, Luc
Jonat, Walter
Beckmann, Matthias W
Schütte, Jochen
Fasching, Peter A
Gottschalk, Nina
Besse-Hammer, Tatiana
Fleischer, Frank
Wind, Sven
Uttenreuther-Fischer, Martina
Piccart, Martine
Harbeck, Nadia

August 2012

Afatinib (BIBW 2992) is an ErbB-family blocker that irreversibly inhibits signaling from all relevan...

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma

De Grève, Jacques
Moran, Teresa
Graas, Marie-Pascale
Galdermans, Daniella
Vuylsteke, Peter
Canon, Jean-Luc
Schallier, Denis
Decoster, Lore
Teugels, Erik
Massey, Dan
Chand, Vikram K
Vansteenkiste, Johan

April 2015

Afatinib, an oral irreversible ErbB family blocker, has demonstrated efficacy in patients with epide...

in

David A. Reardon
Louis B. Nabors
Warren P. Mason
James R. Perry
William Shapiro
Petr Kavan
David Mathieu
Surasak Phuphanich
Agnieszka Cseh
Yali Fu
Julie Cong
Sven Wind

October 2016

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without ...

Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members

Khelwatty, Said Abdullah
Essapen, Sharadah
Seddon, Alan M.
Modjtahedi, Helmout

August 2011

Despite the approval of the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs...

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

De Greve, J.
Teugels, E.
Geers, C.
Decoster, L.
Galdermans, D.
De Mey, J.
Everaert, H.
Umelo, Ijeoma
In't Veld, P.
Schallier, D.

January 2012

Human epidermal growth factor receptor (HER)2/neu kinase domain mutations are found in approximately...

DOI 10.1186/s40064-015-1601-7

Katy Pelling
Sven Wind
Guilhem Bousquet

August 2016

A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients wi...

LUX-breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatinib (L)

Hickish, T
Tseng, LM
Udovitsa, D
Pelling, K
Uttenreuther-Fischer, MM
Mehta, AO
Kovalenko, N
LUX-Breast 2 Study Group
Tsang, J
Huang, CS

January 2012

This journal suppl. is the 2012 ASCO Meeting Abstracts Part 1Open Access JournalGeneral Poster Sessi...

A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole

Gunzer, Katharina
Joly, Florence
Ferrero, Jean-Marc
Gligorov, Joseph
de Mont-Serrat, Helene
Uttenreuther-Fischer, Martina
Pelling, Katy
Wind, Sven
Bousquet, Guilhem
Misset, Jean-Louis

January 2016

International audiencePhase II, open‑label study assessing the efficacy and safety of the ErbB famil...

Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).

Dziadziuszko, Rafal
Smit, Egbert F
Dafni, Urania
Wolf, Juergen
Wasąg, Bartosz
Biernat, Wojciech
Finn, Stephen P
Kammler, Roswitha
Tsourti, Zoi
Rabaglio, Manuela
Ruepp, Barbara
Roschitzki-Voser, Heidi
Stahel, Rolf A
Felip, Enriqueta
Peters, Solange

June 2019

INTRODUCTION Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed in appro...

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck

Seiwert, TY
Fayette, J
Cupissol, D
Del Campo, JM
Clement, Paul
Hitt, R
Degardin, M
Zhang, W
Blackman, A
Ehrnrooth, E
Cohen, EEW

September 2014

Afatinib is an oral, irreversible ErbB family blocker that has shown activity in epidermal growth fa...

Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer

Martin, Nicolas
Isambert, Nicolas
Gomez-Roca, Carlos
Goeldner, Rainer-Georg
Zanetta, Sylvie
Sadrolhefazi, Behbood
de Mont-Serrat, Helene
Campone, Mario
Delord, Jean-Pierre

December 2018

IF 2.808International audienceBackgroundTrastuzumab is the mainstay of therapy for patients with HER...

Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)

Dziadziuszko, Rafal
Smit, Egbert F
Dafni, Urania
Wolf, Juergen
Wasąg, Bartosz
Biernat, Wojciech
Finn, Stephen P
Kammler, Roswitha
Tsourti, Zoi
Rabaglio, Manuela
Ruepp, Barbara
Roschitzki-Voser, Heidi
Stahel, Rolf A
Felip, Enriqueta
Peters, Solange

June 2019

INTRODUCTION Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed in approxi...

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.

Abstract

Extracted data

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.

Abstract

Extracted data

Related items

Related items